Rebalix
Xtrackers · sheet of 10 September 2026
Xtrackers · sheet of 10 September 2026ETF sheet · official issuer and register data
Xtrackers Us Treasuries 3 7 UCITS ETF 1d
XUT7 · LU2662649503 · USD · domicile Luxembourg
Bonds · Government USD · 3-7 years · North AmericaSFDR art. 6 (inferred)
Index tracked: Bloomberg U.S. Treasury 3-7 Year (USD)
- TER
- 0.06%+ trans. 0.01%
- Fund size
- 6 m EUR
- Tracking difference
- —not computable
- 🇮🇹 tax rate
- 12.64%white list 98.93%
- Replication
- Physical
- Income
- Distributingsemi-annual
- Duration
- 4.23 yrsmedium (3–7 years)
Launch 6 Dec 2023 · costs from the KID as of 2 Sept 2026 · 90 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The fund is passively managed.
INVESTMENT OBJECTIVE:
The aim is for your investment to reflect the performance of the Bloomberg US Treasury 3-7 Year Index (index).
DESCRIPTION OF INDEX:
The index reflects the performance of sovereign debt denominated in U.S. Dollars with an outstanding maturity between 3 years and up to, but not including 7 years, issued by the U.S. Government. Only U.S. dollar-denominated, fixed-rate, nominal debt issued by the US Treasury with a maturity between 3 years and up to, but not including 7 years is eligible for inclusion…
Performance since series start (in euro) — base 100
6 Dec 2023 → 8 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +0.8% |
| 3 years | series too young |
| 5 years | series too young |
| 10 years | series too young |
| Since series start | +2.1% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 3.66% | 3.66% | — |
| Max drawdown | −4.88% | −4.88% | — |
| Sharpe | -1.49 | -1.49 | — |
| Sortino | -1.74 | -1.74 | — |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · XUT7 · LU26626495031
RebalixXUT7 · LU2662649503 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +7.22% | +7.27% | −0.06% |
| 2024 | +1.75% | +1.79% | −0.04% |
Fixed income — as declared by the issuer
Issuer page · 20 Aug 2026
Maturity breakdown (% of fund)
Distributions · per share, in USD
Frequency: semi-annual · last 12 months: 1.1054 USD (3.38% of NAV) · last ex-date 19 Aug 2026
| Year | Payments | Total (USD) | Dividend yield |
|---|---|---|---|
| 2026 | 2 | 1.1054 | — |
| 2025 | 2 | 0.9894 | +3.02% |
| 2024 | 1 | 0.429 | +1.32% |
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.
Holdings
Portfolio as declared by the issuer · 2 Sept 2026 · 90 securities · top-10 weight = 18.8%
Countries (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
XUT7 · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 11 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/LU2662649503
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/LU2662649503
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · XUT7 · LU26626495032